We are a group of motivated immunologists and oncologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases.
IL-2 Cancer Immunotherapy
Our first program going into clinical trials is ANV419, a selective interleukin-2 (IL-2) receptor agonist – a type of protein that can enhance a patient’s immune system in order to target and defeat tumors.
Our Immunotherapy Pipeline
Our pipeline includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.
Years of Experience
Million CHF Funding
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
Anaveon appoints Dr Eduard Gasal as Chief Medical Officer
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.
We are committed to developing treatments that benefit patients.
We are developing an IL-2 immunotherapy for cancer.
We are driven by the urgency of patients.
We are backed by more than 146 million CHF of funding.